| Testing Nivolumab to Prevent Disease From Coming Back After Treatment in Patients With Acute Myeloid Leukemia, REMAIN Trial (NCT02275533) | National Cancer Institute (NCI) | 2015-07-02 |
| Study of Palbociclib in MLL-rearranged Acute Leukemias (NCT02310243) | University of Ulm | 2015-07-01 |
| Study of Idarubicin, Cytarabine, and Nivolumab in Patients With High-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) (NCT02464657) | M.D. Anderson Cancer Center | 2015-07-01 |
| Entospletinib Monotherapy and in Combination With Chemotherapy in Adults With Acute Myeloid Leukemia (AML) (NCT02343939) | Gilead Sciences | 2015-07-01 |
| iCare for Cancer Patients (NCT02435550) | University of Florida | 2015-06-26 |
| Sorafenib for Prophylaxis of Leukemia Relapse in Allo-HSCT Recipients With FLT3-ITD Positive AML (NCT02474290) | Nanfang Hospital, Southern Medical University | 2015-06-20 |
| A Study of Selinexor in Combination With Daunorubicin and Cytarabine for Untreated AML (NCT02403310) | H. Lee Moffitt Cancer Center and Research Institute | 2015-06-18 |
| Study of CLAG + Selinexor in Relapsed or Refractory Acute Myeloid Leukemia (NCT02416908) | Washington University School of Medicine | 2015-06-16 |
| AML-02: Omacetaxine With Standard-of-Care Induction With Cytarabine & Idarubicin in Newly-Diagnosed AML Patients (NCT02440568) | University of Illinois at Chicago | 2015-06-05 |
| CD8+ Memory T-Cells as Consolidative Therapy After Donor Non-myeloablative Hematopoietic Cell Transplant in Treating Patients With Leukemia or Lymphoma (NCT02424968) | Robert Lowsky | 2015-06-01 |
| Home Away From Home - Medical Outcomes (NCT02774850) | Children's Hospital of Philadelphia | 2015-06-01 |
| CPX-351 in Treating Patients With Newly Diagnosed, High-Risk Acute Myeloid Leukemia (NCT02286726) | M.D. Anderson Cancer Center | 2015-05-04 |
| A Randomized Placebo-controlled Phase 2 Study of Decitabine With or Without Eltrombopag in AML Patients (NCT02446145) | Technische Universität Dresden | 2015-05-01 |
| Study of Sensitization of Non-M3 AML Blasts to ATRA by Epigenetic Treatment With Tranylcypromine (TCP) (NCT02717884) | Michael Luebbert | 2015-05-01 |
| Ribavirin and Hedgehog Inhibitor With or Without Decitabine in AML (NCT02073838) | Sarit Assouline | 2015-05-01 |
| Use Feasibility of the iThermonitor in Pediatrics Patients on Myelosuppresive Therapies (NCT02410252) | Massachusetts General Hospital | 2015-05-01 |
| Prognostic Role of Minimal Residual Disease in Acute Myeloid Leukemia (NCT02714790) | A.O.U. Città della Salute e della Scienza | 2015-05-01 |
| Ficlatuzumab With High Dose Cytarabine in Relapsed and Refractory AML (NCT02109627) | C. Babis Andreadis | 2015-05-01 |
| A Combination Study of PF-04449913 (Glasdegib) and Azacitidine In Untreated MDS, AML and CMML Patients (NCT02367456) | Pfizer | 2015-04-28 |
| Bortezomib and Vorinostat in Younger Patients With Refractory or Relapsed MLL Rearranged Hematologic Malignancies (NCT02419755) | St. Jude Children's Research Hospital | 2015-04-14 |
| First-in-Human Study of FLX925 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia (NCT02335814) | RAPT Therapeutics, Inc. | 2015-04-08 |
| Crenolanib in Combination With Sorafenib in Patients With Refractory or Relapsed Hematologic Malignancies (NCT02270788) | St. Jude Children's Research Hospital | 2015-04-02 |
| Treatment of Elderly Chinese Acute Myeloid Leukemia Patients Aged 65 to 75 Years Old (NCT02432911) | Jianxiang Wang | 2015-04-01 |
| Treatment of Older Adult Acute Myeloid Leukemia Patients Aged 55 to 65 Years (NCT02432872) | Jianxiang Wang | 2015-04-01 |
| CINC424A2X01B Rollover Protocol (NCT02386800) | Novartis Pharmaceuticals | 2015-03-05 |
| DC Vaccination for Post-remission Therapy in AML (NCT02405338) | Medigene AG | 2015-03-01 |
| Safety Study of Chimeric Antigen Receptor Modified T-cells Targeting NKG2D-Ligands (NCT02203825) | Celyad Oncology SA | 2015-03-01 |
| A Study of ASP2215 in Combination With Induction and Consolidation Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia. (NCT02310321) | Astellas Pharma Inc | 2015-02-26 |
| SL-401 as Consolidation Therapy in Patients With Adverse Risk Acute Myeloid Leukemia in First Complete Remission (NCT02270463) | Stemline Therapeutics, Inc. | 2015-02-01 |
| Velcade and Lenalidomide in Patients With Relapsed AML and MDS After Allogeneic Stem Cell Transplantation (NCT02312102) | Massachusetts General Hospital | 2015-02-01 |
| Telemonitoring Device in Managing Outpatient Care of Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia After Intensive Chemotherapy (NCT02226497) | Fred Hutchinson Cancer Center | 2015-01-09 |
| A Study of ASP2215 in Combination With Induction and Consolidation Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia (NCT02236013) | Astellas Pharma Global Development, Inc. | 2015-01-07 |
| Phase 1 Study of SGI-110 in Patients With Acute Myeloid Leukemia (NCT02293993) | Otsuka Pharmaceutical Co., Ltd. | 2015-01-07 |
| PH 2 ADI-PEG 20 Acute Myeloid Leukemia (NCT01910012) | Polaris Group | 2015-01-06 |
| A Study Assessing tOTX015 in Combination With Azacitidine (AZA) or AZA Single Agent in Patients With Newly-diagnosed Acute Myeloid Leukemia (AML) Not Candidate for Standard Intensive Induction Therapy (SIIT) (NCT02303782) | Oncoethix GmbH, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | 2015-01-01 |
| Peginterferon Alfa-2a to Enhance Anti-leukemic Responses After Allogeneic Transplantation in Acute Myeloid Leukemia (NCT02328755) | University of Michigan Rogel Cancer Center | 2015-01-01 |
| Safety and Efficacy Study of AS101 to Treat Elderly Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) Patients (NCT01010373) | BioMAS Ltd | 2015-01-01 |
| Bridging Study to Eliminate Presence of MRD for Acute Leukemia Before HCT (NCT02349178) | Medical College of Wisconsin | 2014-12-08 |
| A Safety Study of SGN-CD33A in Combination With Standard-of-care in Patients With AML (NCT02326584) | Seagen Inc. | 2014-12-01 |
| Prognostic Factors and the Impact of Various Management of Acute Myeloid Leukemia in Real Life Condition (NCT03284593) | University Hospital, Toulouse | 2014-12-01 |
| Azacytidine Plus FLAG for Relapsed or Refractory AML (NCT02275663) | King Fahad Medical City | 2014-12-01 |
| Idarubicin Plus Cytarabine (IA) vs IA Plus Cladribine (IAC) as Induction Regimen to Treat Initially Diagnosed Acute Myeloid Leukemia (AML) (NCT02323022) | The First Affiliated Hospital of Soochow University | 2014-12-01 |
| Safety and Efficacy of Human Myeloid Progenitor Cells (CLT-008) During Chemotherapy for Acute Myeloid Leukemia (NCT02282215) | Cellerant Therapeutics | 2014-12-01 |
| Study of Dendrogenin A / Oxysterols Balance Between Healthy Volunteers and Acute Myeloid Leukemia Patients (NCT02602587) | University Hospital, Toulouse | 2014-11-25 |
| A Study of RO6870810/TEN-010 in Participants With Acute Myeloid Leukemia and Myelodysplastic Syndrome (NCT02308761) | Hoffmann-La Roche | 2014-11-06 |
| Targeted Marrow Irradiation, Fludarabine Phosphate, and Busulfan Before Donor Progenitor Cell Transplant in Treating Patients With Hematologic Malignancies (NCT02129582) | Case Comprehensive Cancer Center | 2014-11-05 |
| Observational Trial of a Therapeutic Platelet Transfusion Regimen (NCT02276651) | Klinikum Nürnberg | 2014-11-01 |
| Bioequivalence & Food Effect Study in Patients With Solid Tumor or Hematologic Malignancies (NCT02223052) | Celgene | 2014-10-27 |
| Venetoclax and Sequential Busulfan, Cladribine, and Fludarabine Phosphate Before Donor Stem Cell Transplant in Treating Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndrome (NCT02250937) | M.D. Anderson Cancer Center | 2014-10-27 |
| A Phase Ib/II Multicenter Open-label Study of Bemcentinib (BGB324) in Patients With AML or MDS (NCT02488408) | BerGenBio ASA | 2014-10-22 |
| Post-transplantation Cyclophosphamide as GVHD Prophylaxis After HSCT (NCT02294552) | Ivan S Moiseev | 2014-10-01 |
| Phase 1 Study Evaluating ZEN003365 in Relapsed/Refractory Lymphoproliferative Malignancies or Relapsed/Refractory AML (NCT02238522) | Zenith Epigenetics | 2014-10-01 |
| Azacytidine (Vidaza®) Versus Fludarabine and Cytarabine (Fluga Scheme) in Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia (NCT02319135) | PETHEMA Foundation | 2014-10-01 |
| Transplant-Related Mortality in Patients Undergoing a Peripheral Blood Stem Cell Transplantation or an Umbilical Cord Blood Transplantation (NCT02188290) | Kiadis Pharma | 2014-09-01 |
| Tac, Mini-MTX, MMF Versus Tac, MTX for GVHD Prevention (NCT01951885) | Case Comprehensive Cancer Center | 2014-07-07 |
| Adoptive Transfer of Haplo-identical DLI for AML and MDS (NCT02046122) | Duke University | 2014-07-01 |
| Safety Study of Thioridazine in Combination With Cytarabine to Treat Relapsed or Refractory Acute Myeloid Leukemia (NCT02096289) | Ontario Clinical Oncology Group (OCOG) | 2014-07-01 |
| Study of KHK2823 in Patients With Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) (NCT02181699) | Kyowa Kirin, Inc. | 2014-06-01 |
| Sorafenib to Treat FLT3-ITD AML (NCT02156297) | The First Affiliated Hospital of Soochow University | 2014-06-01 |
| Cladribine, Idarubicin, Cytarabine, and Venetoclax in Treating Patients With Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, or Blastic Phase Chronic Myeloid Leukemia (NCT02115295) | M.D. Anderson Cancer Center | 2014-05-19 |
| QUILT-3.018: Neukoplast™ (NK-92) for the Treatment of Refractory or Relapsed Acute Myeloid Leukemia (NCT00900809) | ImmunityBio, Inc. | 2014-05-12 |
| A Phase 1 Dose Escalation and Expanded Cohort Study of EPZ-5676 in the Treatment of Pediatric Patients With Relapsed/Refractory Leukemias Bearing a Rearrangement of the MLL Gene (NCT02141828) | Epizyme, Inc. | 2014-05-01 |
| Early Response Assessment of Induction Chemotherapy in Acute Myeloid Leukemia Patients Using F-18 FLT PET/CT (NCT02103530) | The Catholic University of Korea | 2014-04-01 |
| A Phase 1b Study Evaluating AMG 232 Alone and in Combination With Trametinib in Acute Myeloid Leukemia (NCT02016729) | Kartos Therapeutics, Inc. | 2014-04-01 |
| 1336GCC: Study of Erwinaze for Treatment of Acute Myeloid Leukemia (AML) (NCT02283190) | Ashkan Emadi | 2014-04-01 |
| A Study Of PF-04449913 In Japanese Patients With Select Hematologic Malignancies (NCT02038777) | Pfizer | 2014-03-25 |
| Molecular Characterization of Acute Erythroid Leukemia (M6-AML) Using Targeted Next-generation Sequencing (NCT02861651) | Institut Paoli-Calmettes | 2014-03-01 |
| Safety and Efficacy Study of Microtransplantation to Treat Elderly Acute Myeloid Leukemia (NCT02171117) | The Affiliated Hospital of the Chinese Academy of Military Medical Sciences | 2014-03-01 |
| Standard of Care +/- Midostaurin to Prevent Relapse Post Stem Cell Transplant in Patients With FLT3-ITD Mutated AML (NCT01883362) | Novartis Pharmaceuticals | 2014-02-06 |
| Haplo-SCT vs ASCT With or Without Decitabine in AML CR1 (NCT02059720) | The First Affiliated Hospital of Soochow University | 2014-02-01 |
| Chemo Sensitization Before Hematopoietic Stem Cell Transplantation in Patients With Acute Leukemia in Complete Remission (NCT02605460) | Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran | 2014-02-01 |
| Role of the Therapy Tailored to Risk Factors in Treating Adult Patients (≤60) With Acute Myeloid Leukemia (NCT02072811) | dr hab. n. med. Agnieszka Wierzbowska | 2014-02-01 |
| Irradiation-based Myeloablative Conditioning Followed by Treg/Tcon Immunotherapy in HSCT (NCT03977103) | University Of Perugia | 2014-02-01 |
| Role of PTK-7 in Acute Myeloid Leukemias (NCT02860793) | Institut Paoli-Calmettes | 2014-01-01 |
| Transfusion in Adult Acute Myeloid Leukemia (NCT02899767) | Hospices Civils de Lyon | 2014-01-01 |
| Sulindac for Patients With AML (NCT01843179) | Massachusetts General Hospital | 2014-01-01 |
| T-Regulatory Cell and CD3 Depleted Double Umbilical Cord Blood Transplantation in Hematologic Malignancies (NCT01163201) | Masonic Cancer Center, University of Minnesota | 2014-01-01 |
| Effect of Age on Treatment Decision-Making in Elderly Patients With Acute Myeloid Leukemia (NCT02844218) | Hospices Civils de Lyon | 2014-01-01 |
| Safety and Efficacy Study of Pracinostat With Azacitadine in Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia (AML) (NCT01912274) | Helsinn Healthcare SA | 2013-12-24 |
| Pomalidomide After Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome (NCT02029950) | National Cancer Institute (NCI) | 2013-12-16 |
| Evaluation of 3 Different Doses of IV Busulfan (NCT01985061) | Institut Paoli-Calmettes | 2013-12-01 |
| A Pilot Study of Dociparstat Sodium (ODSH) in Acute Myeloid Leukemia (NCT02056782) | Jazz Pharmaceuticals | 2013-12-01 |
| Clofarabine, Cyclophosphamide and Etoposide for Minimal Residual Disease Positive Acute Leukemia (NCT01677949) | Masonic Cancer Center, University of Minnesota | 2013-12-01 |
| DC Vaccination for Postremission Therapy in AML (NCT01734304) | Ludwig-Maximilians - University of Munich | 2013-11-05 |
| Open-label Clinical Trial to Investigate the Safety and Tolerability of Allogeneic B-cell Concentrates for Immune Reconstitution After Allogeneic Stem Cell Transplantation Measured as Response to a Antedated Single Vaccination (NCT02007811) | University of Erlangen-Nürnberg Medical School | 2013-11-01 |
| A Phase 2 Study of ABT-199 in Subjects With Acute Myelogenous Leukemia (AML) (NCT01994837) | AbbVie | 2013-11-01 |
| A Study of Decitabine (DACOGEN) in Sequential Administration With Cytarabine in Children With Relapsed or Refractory Acute Myeloid Leukemia (NCT01853228) | Janssen Research & Development, LLC | 2013-10-22 |
| Transfusional Iron Overload Among Leukemia Survivors (NCT01965171) | St. Jude Children's Research Hospital | 2013-10-18 |
| Dose Escalation Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics of ASP2215 in Patients With Relapsed or Refractory Acute Myeloid Leukemia (NCT02014558) | Astellas Pharma Global Development, Inc. | 2013-10-09 |
| Interferon for the Intervention of Molecular Relapse in t (8; 21) AML After Allo-HSCT (NCT02027064) | Peking University People's Hospital | 2013-10-01 |
| A Phase 2 Trial to Evaluate the Efficacy and Safety of OCV-501 in Elderly Patients With Acute Myeloid Leukemia (NCT01961882) | Otsuka Pharmaceutical Co., Ltd. | 2013-10-01 |
| Phase II Clofarabine and Cytarabine for Newly Diagnosed Acute Myeloid Leukemia (NCT01960387) | University of Pittsburgh | 2013-10-01 |
| Development of Immunological Assays for the Evaluation of Tumor Antigen Specific Immunity (NCT02016833) | PX Biosolutions | 2013-10-01 |
| Safety Study of CPX-351 in Children With Relapsed Leukemia or Lymphoma (NCT01943682) | Children's Hospital Medical Center, Cincinnati | 2013-09-01 |
| Treatment of Acute Leukemia Relapse After Allotransplantation (NCT01369368) | University of Bergen | 2013-08-01 |
| Ph I Safety and Efficacy of ODSH in Patients Receiving Induction or Consolidation Therapy for Acute Myeloid Leukemia (NCT01843634) | Jazz Pharmaceuticals | 2013-08-01 |
| Idarubicin Overcomes MDR1 Induced Chemoresistance With Higher Induction Remission Rate and Quality Than Daunorubicin in Acute Myeloid Leukemia Patients (NCT01889407) | Nanfang Hospital, Southern Medical University | 2013-08-01 |
| DEC-205/NY-ESO-1 Fusion Protein CDX-1401and Decitabine in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia (NCT01834248) | Roswell Park Cancer Institute | 2013-07-30 |
| Phase 1 Study of CC-486 in Japanese Subjects With Hematological Neoplasms (NCT01908387) | Celgene Corporation | 2013-07-01 |
| A Safety Study of SGN-CD33A in AML Patients (NCT01902329) | Seagen Inc. | 2013-07-01 |